Compare GOOD & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOOD | MNPR |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 624.9M | 587.4M |
| IPO Year | 2003 | 2019 |
| Metric | GOOD | MNPR |
|---|---|---|
| Price | $12.86 | $113.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $12.50 | ★ $107.00 |
| AVG Volume (30 Days) | ★ 324.4K | 155.4K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 9.54% | N/A |
| EPS Growth | N/A | ★ 54.99 |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $161,336,000.00 | N/A |
| Revenue This Year | $9.89 | N/A |
| Revenue Next Year | $2.57 | N/A |
| P/E Ratio | $72.72 | ★ N/A |
| Revenue Growth | ★ 8.00 | N/A |
| 52 Week Low | $10.33 | $46.89 |
| 52 Week High | $13.28 | $124.82 |
| Indicator | GOOD | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 50.72 |
| Support Level | $12.23 | $103.41 |
| Resistance Level | $12.92 | $114.60 |
| Average True Range (ATR) | 0.18 | 6.38 |
| MACD | -0.02 | -0.50 |
| Stochastic Oscillator | 7.06 | 49.12 |
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.